Zhao Jian, Liu Bin, Liu Ning, Zhang Benxia, He Xia, Ma Qizhi, Wang Yongsheng
Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University Chengdu, Sichuan, China.
Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China People's South Road, Section 4, Number 55, Chengdu 610041, Sichuan, China.
Am J Cancer Res. 2022 Nov 15;12(11):4879-4891. eCollection 2022.
Malignant pleural effusion (MPE) is associated with advanced stages of various malignant diseases, especially lung cancer, and is a poor prognostic indicator in these patients. However, the management of MPE remains palliative. A better understanding of the pathogenesis of MPE may lead to the development of new and more effective therapeutic options. Here, we shed light on recent advances in the mechanisms of MPE formation and provide an overview of current targeted therapies for the vascular endothelial growth factor pathway. We also retrospectively enrolled 19 patients with lung adenocarcinoma from the West China Hospital to analyze the efficacy of bevacizumab for MPE using different routes of administration.
恶性胸腔积液（MPE）与各种恶性疾病的晚期相关，尤其是肺癌，并且是这些患者预后不良的指标。然而，MPE的治疗仍然是姑息性的。更好地理解MPE的发病机制可能会带来新的、更有效的治疗选择。在此，我们阐明了MPE形成机制的最新进展，并概述了目前针对血管内皮生长因子途径的靶向治疗。我们还回顾性纳入了来自华西医院的19例肺腺癌患者，以分析贝伐单抗经不同给药途径治疗MPE的疗效。
